MILBEMITE™ OTIC Solution

Manufacturer
Elanco US Inc.
Effective date
2023-12-13
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
12
Source
full-release
Hydrated at
2026-06-01 02:42:40

Label at a glance#

ProductMilbemite
Active ingredientMilbemycin oxime
Label structure14 sections

Storage and handling

MILBEMITE OTIC Solution should be stored at room temperature, between 59° and 77°F (15-25°C).

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

(0.1% milbemycin oxime)

Caution: U.S. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Description:

DESCRIPTION SECTION

MILBEMITE OTIC Solution is available in plastic dispensing tubes. Each plastic tube contains 0.25 mL of MILBEMITE OTIC Solution as a 0.1% solution of milbemycin oxime. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 (C32H45NO7, MW 555.71) and 20% A3 (C31H43NO7, MW 541.68).

Indications:

INDICATIONS & USAGE SECTION

MILBEMITE OTIC Solution is indicated for treatment of ear mite (Otodectes cynotis) infestations in cats and kittens four weeks of age and older. Effectiveness is maintained throughout the life cycle of the ear mite.

Human Warnings:

WARNINGS SECTION

Not for human use. Keep this and all drugs out of the reach of children.

Precautions:

PRECAUTIONS SECTION

The safe use of MILBEMITE OTIC Solution in cats used for breeding purposes, during pregnancy, or in lactating queens, has not been evaluated.

Adverse Reactions:

ADVERSE REACTIONS SECTION

No adverse reactions caused by MILBEMITE OTIC Solution have been reported in controlled effectiveness studies in adult cats and kittens (4 weeks of age).

Dosage:

DOSAGE & ADMINISTRATION SECTION

MILBEMITE OTIC Solution should be administered topically into the external ear canal as the entire contents of a single-dose tube per ear. The volume delivered will be approximately 0.2 mL, with 0.05 mL residual volume remaining in dispensing tube. Repeat the treatment one time if necessary, based upon the ear mite life cycle and the response to treatment.

Administration:

SPL UNCLASSIFIED SECTION

MILBEMITE OTIC Solution should be administered as one tube per ear as a single treatment. Each foil pouch contains two tubes of solution, one for each ear. Open the tube by pressing cap down firmly to break seal. Remove cap and check to be sure tip of tube is open. Squeeze the tube to administer the contents of one tube into each external ear canal. Massage the base of the ear for optimal distribution. In clinical field trials, ears were not cleaned and many animals still had debris in their ears at the end of the study. Cleaning of the external ear canal prior to treatment may be performed, but is not necessary to provide effectiveness.

Effectiveness:

SPL UNCLASSIFIED SECTION

The clinical effectiveness of milbemycin oxime 0.1% solution was evaluated in a placebo-controlled clinical field trial of client-owned cats. Otodectes cynotis infestation was diagnosed by direct microscopic visualization of ear swab debris. Test or placebo treatment was administered to both ears of the cat following the pre-treatment examination. Cats’ ears were examined by ear swab microscopy at multiple intervals throughout the life cycle of the mite (up to day 30). Ninety-nine percent (99%) of the milbemycin oxime-treated group were ear mite negative at the microscopic exams.

Safety:

SPL UNCLASSIFIED SECTION

A study was conducted using otic doses of 0.1, 0.3 or 0.5% milbemycin oxime solutions administered once weekly for six applications in kittens that were 4 weeks of age at the initiation of the study. Otic doses of 0.1 and 0.3% did not produce adverse systemic or local effects. One kitten treated with 0.5% was lethargic 8 hours after the second treatment. The kitten was offered milk replacer and by 10 hours post-treatment it appeared normal. In this kitten, lethargy was not observed after subsequent treatments. A study was conducted to evaluate the safety of a 0.1% milbemycin oxime solution in adult cats. Topical doses at 1X, 3X or 5X the recommended dose applied in one ear did not produce adverse effects.

Storage Conditions:

STORAGE AND HANDLING SECTION

MILBEMITE OTIC Solution should be stored at room temperature, between 59° and 77°F (15-25°C).

How Supplied:

HOW SUPPLIED SECTION

MILBEMITE OTIC Solution is supplied in individual white polypropylene tubes, paired in a foil overlay pouch. The product is packaged in a box of 10 pouches of 2 tubes of 0.25 mL each.

Product of Japan

Manufactured for: Elanco US Inc.
                           Greenfield, IN 46140, USA

Approved by FDA under NADA # 141-163

Milbemite, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2022 Elanco or its affiliates

Revision Date: May 2022

PA103718X

ElancoTM

Principal Display Panel - Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

MilbeMite™

OTIC Solution (0.1% milbemycin oxime)

A topical medication for the treatment of ear mite
(Otodectes cynotis) infestations in cats and kittens.

FOR USE IN CATS & KITTENS
FOUR WEEKS OF AGE AND OLDER

Net Contents:
10 pouches of
2 tubes of
0.25 mL each

Principal Display Panel - Carton Label
Principal Display Panel - Carton Label

Principal Display Panel - Pouch Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

MilbeMite™

OTIC Solution (0.1% milbemycin oxime)

For the treatment of ear mite (Otodectes cynotis)
infestations in cats and kittens.

FOR USE IN CATS & KITTENS FOUR WEEKS OF
AGE AND OLDER

Net Contents: 2 tubes of 0.25 mL each

HUMAN WARNINGS:
Not for human use. Keep this and all drugs out
of the reach of children.

CAUTION: Federal (USA) law restricts this drug
to use by or on the order of a licensed veterinarian.

Principal Display Panel - Pouch Label Front
Principal Display Panel - Pouch Label Front
Principal Display Panel - Pouch Label Back
Principal Display Panel - Pouch Label Back

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
545172MilbeMite 0.1 % Otic SolutionPSN12
545168milbemycin oxime 0.1 % Otic SolutionPSN12
545172milbemycin oxime 1 MG/ML Otic Solution [MilbeMite]SBD12
545168milbemycin oxime 1 MG/ML Otic SolutionSCD12
545172MilbeMite 0.1 % Otic SolutionSY12
545172MilbeMite 1 MG/ML Otic SolutionSY12
545168milbemycin oxime 0.1 % Otic SolutionSY12

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
58198-8602-5Milbemite10 in 1 BOXSOLUTION1012
58198-8602-5Milbemite2 in 1 POUCHSOLUTION212

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
58198-8602MILBEMITE (MILBEMYCIN OXIME) SOLUTION [ELANCO US INC.]122 package rows20231219_ea41ec41-0514-4a24-bec7-d1bb06f5d4ea.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
MILBEMYCIN OXIMEACTIVE INGREDIENT0502PUN0GT8
MILBEMYCIN OXIMEACTIVE MOIETY0502PUN0GT8

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 2 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
58198-860258198-8602-5

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
Milbemycin oxime0502PUN0GTACTIB

Source Document#

Source XML

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.